Document Detail


Androgen in the treatment of refractory anemia.
MedLine Citation:
PMID:  1747444     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We retrospectively evaluated the efficacy of androgen in the treatment of refractory anemia (RA) and compared patient characteristics and the probability of survival in androgen-responder and nonresponder groups. Forty patients with RA were treated in our hospital between 1975-1989, and 27 were treated with various derivatives of androgen. Eleven of the latter responded effectively to androgen therapy, representing an efficacy rate of 40.7%, higher than that of any other treatments thus far reported. The probability of 10-year survival estimated by the Kaplan-Meier method was 75.0% for the responder group and 41.3% for nonresponders, with a median follow-up of 1202 and 1272 days, respectively. In addition, the percent probability of transformation-free survival was higher among androgen-responders than among nonresponders, though the difference was not significant. Transformation from RA to RAEB or overt leukemia was seen in only one case among the former group, but in six among the latter. With respect to patient characteristics, only the percentage of marrow myeloblasts differed significantly between the groups.
Authors:
R Kobaba; A Kanamaru; Y Takemoto; M Kohsaki; E Kakishita; K Nagai
Related Documents :
21639934 - Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouraci...
22175254 - High-dose chemotherapy with autologous stem cell support in patients with metastatic no...
17252564 - Outcomes in childhood aml in the absence of transplantation in first remission--childre...
19484734 - Intensive induction chemotherapy with regimen containing intermediate dose cytarabine i...
9803354 - The value of pretreatment clinical and biochemical parameters in staging and prognostic...
11251014 - Localized ewing tumor of bone: final results of the cooperative ewing's sarcoma study c...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of hematology     Volume:  54     ISSN:  0925-5710     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  1991 Apr 
Date Detail:
Created Date:  1992-01-21     Completed Date:  1992-01-21     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  103-7     Citation Subset:  IM    
Affiliation:
2nd Department of Internal Medicine, Hyogo College of Medicine, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Androstanols / therapeutic use*
Anemia, Refractory / drug therapy*,  mortality
Danazol / therapeutic use*
Drug Evaluation
Fluoxymesterone / therapeutic use*
Follow-Up Studies
Humans
Life Tables
Methenolone / analogs & derivatives*,  therapeutic use
Middle Aged
Retrospective Studies
Chemical
Reg. No./Substance:
0/Androstanols; 153-00-4/Methenolone; 17230-88-5/Danazol; 21362-69-6/mepitiostane; 434-05-9/methenolone acetate; 76-43-7/Fluoxymesterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Animal toxicology studies on new medicines and their relationship to clinical exposure: a review of ...
Next Document:  Enzyme histochemical, immuno histochemical and electron microscopic studies of two cases of leukemic...